CTLA4 and head and neck squamous cell carcinoma: This indicates that in COSCC, similar to human tumors, there is increased expression of PD-L1 and CTLA-4 that correlates with expression of EMT markers, suggesting that patients with COSCC could benefit from immune checkpoint inhibitor therapies, in a manner comparable to results from currently ongoing trials with HNSCC [23].